Pensioenfonds Rail & OV bought a new stake in shares of Cencora, Inc. (NYSE:COR – Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 32,628 shares of the company’s stock, valued at approximately $9,797,000. Cencora makes up about 2.6% of Pensioenfonds Rail & OV’s holdings, making the stock its 9th biggest holding.
Several other hedge funds and other institutional investors have also recently modified their holdings of COR. BlackRock Inc. bought a new stake in Cencora during the 2nd quarter worth approximately $5,154,136,000. Bank of America Corp DE boosted its holdings in Cencora by 6.9% in the 1st quarter. Bank of America Corp DE now owns 4,138,388 shares of the company’s stock valued at $1,300,033,000 after purchasing an additional 267,318 shares during the period. Amundi boosted its holdings in Cencora by 43.5% in the 2nd quarter. Amundi now owns 2,229,326 shares of the company’s stock valued at $630,855,000 after purchasing an additional 676,066 shares during the period. Carmignac Gestion boosted its holdings in Cencora by 58.7% in the 2nd quarter. Carmignac Gestion now owns 1,747,363 shares of the company’s stock valued at $494,463,000 after purchasing an additional 646,112 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Cencora during the 2nd quarter valued at $483,772,000. 97.52% of the stock is currently owned by institutional investors.
Cencora Trading Up 2.8%
NYSE COR traded up $9.74 during trading on Friday, hitting $359.12. 1,393,211 shares of the company’s stock traded hands, compared to its average volume of 1,421,795. The stock has a fifty day moving average of $327.12 and a two-hundred day moving average of $317.20. Cencora, Inc. has a 12-month low of $244.82 and a 12-month high of $377.54. The firm has a market cap of $68.53 billion, a P/E ratio of 20.04, a PEG ratio of 1.81 and a beta of 0.58. The company has a debt-to-equity ratio of 3.01, a current ratio of 0.94 and a quick ratio of 0.59.
Cencora (NYSE:COR – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $4.66 EPS for the quarter, topping analysts’ consensus estimates of $4.58 by $0.08. Cencora had a return on equity of 110.72% and a net margin of 1.03%. The business had revenue of $88.35 billion for the quarter, compared to analysts’ expectations of $87.95 billion. During the same period in the previous year, the firm earned $3.84 EPS. The business’s quarterly revenue was up 5.5% on a year-over-year basis. As a group, sell-side analysts expect that Cencora, Inc. will post 19.58 EPS for the current year.
Cencora Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Monday, November 30th. Stockholders of record on Friday, November 13th will be paid a dividend of $0.66 per share. This represents a $2.64 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, November 13th. This is a positive change from Cencora’s previous quarterly dividend of $0.60. Cencora’s payout ratio is presently 13.39%.
Insider Transactions at Cencora
In other Cencora news, EVP Elizabeth Campbell sold 11,300 shares of the company’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the transaction, the executive vice president owned 19,455 shares in the company, valued at approximately $6,305,754.60. This represents a 36.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.38% of the stock is currently owned by insiders.
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on COR. JPMorgan Chase & Co. increased their price objective on Cencora from $390.00 to $413.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 10th. Wall Street Zen upgraded Cencora from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Weiss Ratings upgraded Cencora from a “buy (b-)” rating to a “buy (b)” rating in a research note on Tuesday, October 6th. Wells Fargo & Company upped their target price on Cencora from $331.00 to $395.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 11th. Finally, Citigroup reaffirmed a “buy” rating on shares of Cencora in a report on Thursday, August 6th. Twelve research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $368.14.
Read Our Latest Stock Report on Cencora
Cencora Company Profile
Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical services company that connects pharmaceutical manufacturers with healthcare providers. Its core business includes sourcing and distributing medicines and other healthcare products to pharmacies, hospitals, health systems and other care providers. The company also provides services supporting specialty pharmaceuticals, including logistics, consulting and solutions for manufacturers and healthcare organizations. These services help manage the handling and delivery of complex medicines and support access to treatments.
Further Reading
- Five stocks we like better than Cencora
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR – Free Report).
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.
